Please select the option that best describes you:
Topics:
Pediatric Hematology/Oncology • ALL
Can therapy safely be reduced to 2 years for males with pediatric T-cell leukemia?
Based on St. Judes, DFCI, and BFM data, COG has recently decreased the length of therapy for males with B-Cell ALL. Can this be extrapolated to T-cell ALL as well?
Answer from: at Academic Institution
It is an open research question and it cannot be assumed that T cell ALL would have the same outcome. Given that the salvage rate for relapse T cell ALL is so low, this should be addressed in a clinical trial.
Sign in or Register to read more